Editor's Note

Paul, Reid
April 2009
Pharmaceutical Representative;Apr2009, Vol. 39 Issue 4, p3
In this article the author focuses on the condition of pharmaceutical industry in the U.S. The author highlights the consolidation of several companies in the industry including Pfizer and Wyeth, Merck and Schering-Plough, and Spectrum and RIT Oncology. The author cites the deal condition of stockholders. Moreover, the author also looks on the survivability of pharmaceutical representatives.


Related Articles

  • By the Numbers.  // Pharmaceutical Representative;Apr2009, Vol. 39 Issue 4, p5 

    The article focuses on the efforts of several pharmaceutical companies and sales representatives in ameliorating their sales. It mentions that these companies and representatives are looking for physicians with good practices in order to accelerate their sales. A research conducted by the...

  • Get on the list (and stay there!). Warner, K. C. // Pharmaceutical Representative;Dec2006, Vol. 36 Issue 12, p22 

    The article discusses strategies to be applied by pharmaceutical representatives to sell their products to hospital pharmacies. The first step to be taken by the representative is to know the pharmacy and the members of the committee. To sell the product successfully, the agent should convince...

  • Reducing the billions spent on sales forces.  // Medical Marketing & Media;Jan2005, Vol. 40 Issue 1, p6 

    The article reports that pharmaceutical companies spend over $20 billion in marketing annually, and at least $12 billion of that goes to detailing. More than 90,000 salespeople focus on selling and providing samples to about one million doctors in the U.S. It is a big operation with a long and...

  • If a tree falls …. Edwards, Jim // Pharmaceutical Representative;Oct2007, Vol. 37 Issue 10, p26 

    The article offers tips on how to become an effective emotion-based sales personnel in the pharmaceutical industry.

  • Hard at work.  // Pharmaceutical Representative;Aug2007, Vol. 37 Issue 8, p3 

    The article discusses various reports published within the issue including one by Marjorie Brody on becoming a good pharmaceutical sales representative, and another by Sharon L. Marshall on the pros and cons of contract sales.

  • Surveys question efficiency of expanded field forces in accessing and selling doctors.  // Medical Marketing & Media;Feb2000, Vol. 35 Issue 2, p18 

    Reports that two studies are questioning whether the premise and productivity of expanded sales forces of pharmaceutical companies in the United States bring expected returns. Study by Health Strategies Group which revealed that a large percentage of sales calls to high prescribers allow less...

  • When Will the Bubble Burst? Goldberg, Michele; Davenport, Bob; Mortellito, Tiffany // Pharmaceutical Executive;Jan2003, Vol. 23 Issue 1, p44 

    Discusses the 2002 compensation module of the Hay Group's annual Sales Force Effectiveness Study for the pharmaceutical industry. Percentage of companies that expanded their sales forces; Slowdown in the use of contract sales organizations; Pressure on company recruiters to hire additional...

  • Takes one to know one: reps choose top sales forces, tell what makes them tick.  // Medical Marketing & Media;Jun2000, Vol. 35 Issue 6, p6 

    Reports on the top pharmaceutical companies in terms of effectiveness of sales forces. Sales representatives' ranking of the companies; Pfizer; Merck; Bristol-Myer; Glaxo Wellcome; SmithKline Beecham; Eli Lilly.

  • The Community.  // Pharmaceutical Representative;Jul2005, Vol. 35 Issue 7, p36 

    Reports on career developments involving sales executives in the pharmaceutical industry. Promotion of Christopher McDonald from senior sales representative to regional training specialist for the central region of Abbott Laboratories Inc.; Selection of Lisa McLaughlin as hospital sales...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics